Pharming Group announces the 2024 Annual General Meeting of Shareholders
04 avr. 2024 02h30 HE
|
Pharming Group N.V.
Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company’s 2024 Annual General Meeting of...
Pharming Group announces the filing of its 2023 Annual Report and Form 20-F
04 avr. 2024 01h00 HE
|
Pharming Group N.V.
Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended...
Pharming Group to participate in April investor conferences
03 avr. 2024 02h00 HE
|
Pharming Group N.V.
Leiden, The Netherlands, April 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group reports fourth quarter and full year 2023 financial results
14 mars 2024 02h00 HE
|
Pharming Group N.V.
Full year 2023 total revenues increased by 19% to US$245.3 millionRecord fourth quarter RUCONEST® revenues of US$73.3 million resulted in a 10% increase in full year 2023 RUCONEST® revenues to...
Pharming Group to report fourth quarter and full year 2023 financial results on March 14
29 févr. 2024 02h00 HE
|
Pharming Group N.V.
Leiden, The Netherlands, February 29, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year...
Pharming Group to participate in February investor conferences
08 févr. 2024 02h00 HE
|
Pharming Group N.V.
Leiden, The Netherlands, February 8, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
08 janv. 2024 01h00 HE
|
Pharming Group N.V.
Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end ...
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)
13 déc. 2023 01h00 HE
|
Pharming Group N.V.
Initial development in PIDs with immune dysregulation linked to PI3Kẟ signaling Phase 2 clinical trial initiation planned for 2Q 2024 Leiden, The Netherlands, December...
Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib
21 nov. 2023 01h00 HE
|
Pharming Group N.V.
The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The...
Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval
10 nov. 2023 08h51 HE
|
Pharming Group N.V.
Leiden, The Netherlands, November 10, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has received a Day 180 Second List of...